Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAH-1005 in Refractory Differentiated Thyroid Cancer
NCT05275946Phase 1Completed
- Sponsor
- The University of Osaka
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of sodium astatide (211At) in differentiated thyroid cancer (DTC), sponsored by The University of Osaka. Primary endpoints: Treatment-related adverse events as assessed by CTCAE v5.0 at 6 months and Dose Limiting Toxicity at 4 weeks. Started Nov 2021; status: completed.
02
Drugs
sodium astatide (211At)
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT05275946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275946.